CORE TECHNOLOGIES
Organ-on-Chip
Microfluidic devices recreating organ physiology. First FDA ISTAND acceptance (Emulate, Sept 2024). Types: liver, lung, heart, kidney, brain, gut chips. 40% CAGR—fastest growing segment.
Complete Guide →Organoids
Self-organizing mini-organs from stem cells. 87%+ drug response accuracy (tumor organoids). Types: brain, liver, kidney, gut, tumor, lung. Merck acquired HUB Organoids (Dec 2024).
Complete Guide →Digital Twins
Virtual patient models simulating individual physiology. HeartFlow deployed across 725+ hospitals. FDA Enrichment Playbook (Oct 2024). In-silico clinical trials.
Complete Guide →iPSC Technology
Induced pluripotent stem cells enabling patient-specific disease modeling. Powers "Clinical Trials in a Dish." CiPA Initiative for cardiotoxicity. 20+ differentiated cell types available.
Complete Guide →EMERGING TECHNOLOGIES
IBM Quantum, Google, IonQ partnerships with pharma. McKinsey: $200-500B value by 2035. Protein folding, molecular simulation applications.
Connected organ chips modeling systemic drug effects. DARPA 10-organ Interrogator. Wyss Institute 15+ organ coupling. Off-target toxicity detection.
Fused organoids modeling organ-organ interactions. Cortico-striatal assembloids with functional neural circuits. Parkinson's disease research applications.